Health affairs scholar

Differences by social and demographic factors in prescribing semaglutide and tirzepatide for obesity treatment

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Substantial effectiveness in weight management has been observed with semaglutide and tirzepatide.

  • Evidence regarding treatment inequities for these medications is limited.
  • The study evaluates trends over time in the prescription of semaglutide and tirzepatide.
  • Sociodemographic disparities in access to these treatments are assessed.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Aug '25
Weight Loss with Semaglutide and Tirzepatide in People with Overweight or Obesity Without Diabetes
top 20% journal
cited by 23 papers
journal article
Jun '25
Summary of studies comparing how well GLP-1 receptor agonists work for weight loss
top 10% journal
cited by 5 papers
systematic review
Mar '25
Differences across regions in starting new GLP-1 medicines among adults eligible for obesity treatment
top 5% journal
cited by 19 papers
journal article
Jul '26
Real-world weight loss with different GLP-1 medicines in the All of Us study
top 20% journal
comparative study
Jun '25
Comparing effectiveness and safety of tirzepatide (10 and 15 mg) and semaglutide (2.4 mg) for treating obesity and overweight in type 2 diabetes patients
top 5% journal
cited by 10 papers
randomized controlled trial
Apr '26
Cost-effectiveness of tirzepatide compared to semaglutide for US patients with obesity or overweight in a direct phase 3 trial
top 20% journal
clinical trial, phase iii
Mar '26
Comparing the effectiveness and safety of Tirzepatide, Liraglutide, and Semaglutide for treating obesity without diabetes
top 20% journal
cited by 5 papers
journal article
Jul '24
Weight Loss with Semaglutide Compared to Tirzepatide in Overweight or Obese Adults
top 2% journal
cited by 263 papers
observational study
Jun '25
Use of GLP Medications for Adult Obesity by Race, Ethnicity, and Income in a University Health System
top 5% journal
journal article
Jun '26
Real-world weight and blood sugar outcomes of tirzepatide versus semaglutide in people with obesity and type 2 diabetes
observational study

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #59
GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes
2 weeks ago7 studies
issue #58
A new triple receptor drug cut body weight by nearly 20% in 24 weeks
3 weeks ago7 studies
issue #57
A triple-receptor obesity drug just posted 25–35% weight loss in a phase 3 trial
4 weeks ago7 studies
issue #56
Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it
5 weeks ago7 studies
issue #55
The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated
6 weeks ago7 studies
issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
7 weeks ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
8 weeks ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
9 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
10 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
11 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief